Psychiatr. praxi. 2013;14(3):106-110

Pharmacotherapy of child and adolescent psychiatry

doc.MUDr.Eva Malá, CSc.
Denní psychoterapeutické sanatorium Ondřejov, Neurologická klinika 1. LF UK a VFN v Praze

When you deploy pharmacotherapy in children you need to consider the following aspects: development, maturity, society and communication.

The article discussed only pharmacotherapy medications although of course a treatment would include a combination of

psychotherapy, pharmacotherapy and sociotherapy.

Marginally there are mentioned findings in well-defined diagnostic units by imaging methods and practices supportive of some therapeutic

procedures „off-label“.

Keywords: psychoactive drugs and their use „on and off label“ for specific diagnoses in child and adolescent psychiatry

Published: August 7, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malá E. Pharmacotherapy of child and adolescent psychiatry. Psychiatr. praxi. 2013;14(3):106-110.
Download citation

References

  1. Sowell ER, Thompson PM, Leopard ChM, et al. Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosc 2004; 22-24: 8223-8231. Go to original source... Go to PubMed...
  2. Mattai A, Hosanagar A, Weisinger B, et al. Hippocampal volume development in healthy siblings of childhood-onset schizophrenia patients. Am J Psychiatry 2011; 168(4): 427-435. Go to original source... Go to PubMed...
  3. Aas M, Navari S, Gibbs A, Mondelli, et al. Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis? Schizophr Res 2012; 137(1-3): 73-79. Go to original source... Go to PubMed...
  4. Pitman RK, Shin LM, Rauch SL. Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. J Clin Psychiatry 2001; 62(Suppl 17): 47-54.
  5. Galvan A, Hare T, Parra C, et al. Earlier Development of the Accumbens Relative to Orbitofrontal Cortex Might Underlie Risk-Taking Behavior in Adolescents. J Neurosci 2006; 26: 6885-6892. Go to original source... Go to PubMed...
  6. Erwin RJ, Gur RC, Gur RE, et al. Facial emotion discrimination 1: task construction and behavioral findings in normal subjects. Psychiatry Res. 1992; 42: 231-240. Go to original source... Go to PubMed...
  7. Damasio D. Face agnosia and the neural substrates of memory. Annu Rev Neurosci. 1990; 13: 89-109. Go to original source... Go to PubMed...
  8. Adolphs R. Neural systems for recognizing emotion. Curr Opin Neurobiol. 2002; 12: 169-177. Go to original source... Go to PubMed...
  9. Vytal K, Hamann S. Neuroimaging support for discrete neural correlates of basic emotions: A voxel-based meta-analysis. J Cognitive Neurosci 2010; 22(12): 2864-2885. Go to original source... Go to PubMed...
  10. Gur RE, McGrath C, Chan RM, et al. An fMRI study of facial emotion processing in schizophrenia. Am J Psychiatry 2002; 159: 1992-1999. Go to original source... Go to PubMed...
  11. Mandal MK, Pandey R, Prasad AB. Facial expressions of emotions and schizophrenia: review. Schizophr Bull 1998; 24: 399-412. Go to original source... Go to PubMed...
  12. Nelson MD, Saykin AJ, Flashman LA, et al. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 1998; 55: 433-440. Go to original source... Go to PubMed...
  13. Birbaumer N, Grod W. fMRI reveals amygdala activation to human faces in social phobics. Neureport 1998; 9: 1223-1226. Go to original source... Go to PubMed...
  14. Drtílková I. Sociální fobie (sociálně úzkostná porucha v dětství a adolescenci). Psychiatrie 2001; 2: 99-106.
  15. Biederman J, Hirshfeld-Becker D, Rosenbaum J, et al. Further Evidence of Association Between Behavioral Inhibition and Social Anxiety in Children. Am J Psychiatry 2001; 158: 1673-1679. Go to original source... Go to PubMed...
  16. Hanson J, Pollak S, Chung M, et al. Early Stress is Associated with Alterations in the Orbitofrontal Cortex: A Tensor-Based Morphometry Investigation of Brain Structure and Behavioral Risk. J Neurosci 2010; 30: 7466-7472. Go to original source... Go to PubMed...
  17. Aas M, Navari S, Gibbs A, et al. Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis? Schizophr Res 2012; 137(1-3): 73-79. Go to original source... Go to PubMed...
  18. Battaglia M, Ogliari A, Zanoni A, et al. Influence of the Serotonin Transporter Promoter Gene and Shyness on Children's Cerebral Responses to Facial Expressions. Arch Gen Psychiatry 2005; 62: 85-94. Go to original source... Go to PubMed...
  19. Malá E. Úzkostné poruchy v dětství. Čes a slov Psychiatr 2011; 107(2): 99-105.
  20. Schwarz C, Wright Ch, Shin L. Inhibited and Uninhibited Infants "Grown Up": Adult Amygdalar Response to Novelty. Arch Gen Psychiatry 2003; 62: 85-94. Go to original source... Go to PubMed...
  21. Schwarz C, Wright Ch, Shin L, et al.Differential Amygdalar Response to Novel versus Newly Familiar Neutral Faces: A Functional MRI Probe Developed for Studying Inhibite Temperament. Biolog Psych 2001; 53: 854-862. Go to original source... Go to PubMed...
  22. Dolan RJ. Emotional Processing in the human brain revealed through functional neuroimaging. In: MS Gazzaniga (Ed.), The New Cognitive Neurosciences Cambridge 2000; 1: 115-1131. Go to PubMed...
  23. Drtílková I. Současný pohled na suicidální riziko v průběhu antidepresivní léčby u dětí. Čes a slov Psychiat 2007; 103: 22-27.
  24. Drtílková I, Hrdlička M, Paclt I. Hyperkinetické poruchy u dětí. In: Raboch J, et al. Psychiatrie: Praha, Psychiatrická společnost ČLS JEP 2006: 141-149.
  25. Goetz M, Uhlíková P. ADHD porucha pozornosti s hyperaktivitou. Praha: Galen 2011: 160.
  26. Paclt I. Biologické základy hyperkinetické poruchy a možnosti farmakologické léčby. Remedia 2005; 15: 484-490.
  27. Malá E, Kučera Z. Atomoxetin. Remedia 2007; 6: 542-550.
  28. Malá E. Farmakoterapie ADHD. Postgraduální medicina 2012; 14: 24-33.
  29. Goetz M. Současný pohled na léčbu ADHD. Remedia 2009; 19: 190-196.
  30. Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012; 129(3): 771-784. Go to original source... Go to PubMed...
  31. Cohen D, Bonnot O, Bodeau N, et al. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012; 32(3): 309-316. Go to original source... Go to PubMed...
  32. Keshavan MS, Tandon R, Nasrallah HA. Schizophrenia,, ,just the facts" Treatment and prevention. Past, present, and future. Schizophr Res 2010; 122: 1-23. Go to original source... Go to PubMed...
  33. Racková S, Janů L. Proč také pacienti nechtějí antipsychotika? Psychiatr pro praxi 2007; 4: 166-168.
  34. Drtílková I, Theiner P. Aripiprazol v off-label indikaci léčby Tourettova syndromu. Čes a slov Psychiatr 2010; 106(2): 107-110.
  35. Husman C, Coffey BI, Schlechter R, et al. Aripiprazole in children and adolescents with Touerette disorder with and without explosive outbbursts. J Child Adolesc Psychopharmacol 2008; 18(5): 509-515. Go to original source... Go to PubMed...
  36. Davies I, Stern JS, Agrawal N, et al. A case series of patiens with Touretteś syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006; 21(7): 447-453. Go to original source... Go to PubMed...
  37. Duane DD. Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol 2006; 21(4): 358. Go to original source... Go to PubMed...
  38. Malá E. Léčba Touretteova sy aripiprazolem u dětí a adolescentů - observační studie. Čes a slov Psychiatr 2011; 107(6): 321-323.
  39. Přikryl R, Kašpárek T. Hluboká mozková stimulace a její využití v léčbě deprese. Čes a slov psychiatr 2010; 106(3): 179-182.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.